Symposium 13 Vulnerable patient: an endless debate

[S13-6] Is the capping and sealing of vulnerable plaque with a coronary device clinically feasible?: Update from PROSPECT II

^○Maehara Akiko (Columbia University/Cardiovasucular Reserch Foundation, USA)

Keywords:PROSPECT ABSORB was designed to randomize patients to treatment with guideline-directed medical therapy with versus without implantation of bioresorbable scaffolds for non-flow limiting vulnerable plaque, defined as a plaque burden ≥70%. PROSPECT ABSORB successfully randomized 182 patients and all patients will complete the primary endpoint of 2-year follow-up in December 2019. For intracoronary device therapy to be warranted, it must be more beneficial than medical therapy alone. The concept of “plaque sealing” will be discussed.